Takeda Pharmaceuticals (TYO:4502) yesterday launched a wearable watch pilot program to help people suffering with inflammatory bowel disease track their symptoms.
Takeda said they will roll out the program, iBData, with 100 patients tracking their daily symptoms and lifestyle factors.
Then, the data is collected into a report that is shared with the patient’s doctor, in the hopes of personalizing treatment to the patient’s symptoms. Tracking data regularly can help create an ongoing dialogue with the doctor and patient between multiple visits, according to the company.
Takeda is partnering with Texas Digestive Disease Consultants and Vanderbilt University Medical Center for the pilot.
“The wearable aspect of the technology being used for iBData provides an opportunity to investigate how we as physicians monitor, assess and treat our patients,” Dr. Tim Ritter of TDDC’s Luminal Research Division said in a press release.
“We are very excited about this project and its potential for both patients and physicians,” Dr. Dawn Beaulieu of VUMC said in a prepared statement. “Giving patients the power to capture robust, real-time monitoring of their symptoms will help us as physicians to create a personalized treatment plan. Our hope is that this will ultimately result in better disease control and improved IBD care.”
“At Takeda, part of what fuels our ongoing dedication to advanced research in the field of gastroenterology is our deep understanding of the challenges that dictate unique needs for both patients and physicians managing IBD,” Takeda specialty business unit veep & head Stephanie Brown said in prepared remarks. “iBData leverages the remarkable capabilities available today when wearable technologies and medicine converge, in an effort to help overcome these challenges. This innovative pilot program will explore new ways to transform care by generating novel insights into the patient experience that physicians can directly utilize.”
